BRPI0413608A - composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero - Google Patents
composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìferoInfo
- Publication number
- BRPI0413608A BRPI0413608A BRPI0413608-0A BRPI0413608A BRPI0413608A BR PI0413608 A BRPI0413608 A BR PI0413608A BR PI0413608 A BRPI0413608 A BR PI0413608A BR PI0413608 A BRPI0413608 A BR PI0413608A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- receptor antagonist
- opioid receptor
- ligand
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
Abstract
"COMPOSIçãO FARMACêUTICA COMPREENDENDO UM LIGANTE ALFA2DELTA E UM ANTAGONISTA DE RECEPTOR OPIóIDE PARA A PREVENçãO E TRATAMENTO DE DEPENDêNCIA QUìMICA EM UM MAMìFERO". São divulgadas composições farmacêuticas para o tratamento de dependência ou vício em álcool ou cocaína, dependência ou vício em tabaco, redução da síndrome de abstinência de álcool ou auxílio na cessação ou diminuição de uso de álcool e abuso de substancias ou outras dependências comportamentais incluindo jogos de azar. As composições farmacêuticas se compreendem de uma combinação terapeuticamente eficaz de um antagonista de receptor opióide e um ligante alfa2delta e um veículo farmaceuticamente aceitável. O uso destes compostos é também divulgado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49737203P | 2003-08-22 | 2003-08-22 | |
PCT/IB2004/002602 WO2005018670A1 (en) | 2003-08-22 | 2004-08-09 | Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413608A true BRPI0413608A (pt) | 2006-10-17 |
Family
ID=34216118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413608-0A BRPI0413608A (pt) | 2003-08-22 | 2004-08-09 | composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050043345A1 (pt) |
EP (1) | EP1658098A1 (pt) |
BR (1) | BRPI0413608A (pt) |
CA (1) | CA2535814A1 (pt) |
MX (1) | MXPA06002024A (pt) |
WO (1) | WO2005018670A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2499994C (en) * | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
KR100774625B1 (ko) * | 2003-09-25 | 2007-11-08 | 워너-램버트 캄파니 엘엘씨 | 치료제 베타 아미노산 |
US8452656B2 (en) * | 2005-06-29 | 2013-05-28 | Google Inc. | Prioritizing ad review, by using expected revenue for example, in an advertising system |
EP3072884B1 (en) | 2013-11-20 | 2020-01-01 | Sanwa Kagaku Kenkyusho Co., Ltd. | 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes |
AU2016265801B2 (en) | 2015-05-20 | 2020-10-08 | Ube Corporation | Crystal of salt of novel 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1402638A (zh) * | 1999-11-06 | 2003-03-12 | 艾伯特·舒尔曼 | 一种治疗物质成瘾的方法 |
US20020187996A1 (en) * | 2001-05-14 | 2002-12-12 | Dewey Stephen L. | Prevention of addiction in pain management |
GB0225379D0 (en) * | 2002-10-31 | 2002-12-11 | Pfizer Ltd | Therapeutic proline derivatives |
CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
US7056930B2 (en) * | 2003-04-14 | 2006-06-06 | Pfizer Inc. | 2-Azabicyclo[3.3.1]nonane derivatives |
BRPI0409307A (pt) * | 2003-04-14 | 2006-04-25 | Pfizer Prod Inc | derivados de 3-azabiciclo[3.2.1]octano |
-
2004
- 2004-06-17 US US10/870,821 patent/US20050043345A1/en not_active Abandoned
- 2004-08-09 BR BRPI0413608-0A patent/BRPI0413608A/pt not_active Application Discontinuation
- 2004-08-09 WO PCT/IB2004/002602 patent/WO2005018670A1/en not_active Application Discontinuation
- 2004-08-09 EP EP04744237A patent/EP1658098A1/en not_active Withdrawn
- 2004-08-09 CA CA002535814A patent/CA2535814A1/en not_active Abandoned
- 2004-08-09 MX MXPA06002024A patent/MXPA06002024A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20050043345A1 (en) | 2005-02-24 |
MXPA06002024A (es) | 2006-05-17 |
CA2535814A1 (en) | 2005-03-03 |
EP1658098A1 (en) | 2006-05-24 |
WO2005018670A1 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200100241T2 (tr) | Nosiseptin reseptörü ORL-1 için yüksek çekim gücü olan ligandlar | |
Carroll et al. | Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist | |
RU2428985C2 (ru) | Лекарственная форма, содержащая оксикодон и налоксон | |
BRPI0413693A (pt) | composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero | |
IS7142A (is) | Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi | |
WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
BRPI0507497A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5 | |
WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
TR200001942T2 (tr) | Opioid agonist/antagonist kombinasyonlar | |
DE60231911D1 (de) | Sedierende und nicht sedierende antihistamine enthaltende zusammensetzungen | |
ATE423556T1 (de) | Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen | |
WO2004093819A3 (en) | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
ES2181055T3 (es) | Formulaciones galenicas que contienen antagonistas de opiaceos. | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
BRPI0412557A (pt) | forma de dosagem farmacêutica de eventos cardiovasculares | |
NZ563678A (en) | Synergistic modulation of FLT3 kinase using 4-cyano-1H-imidazole-2-carboxylic acid{2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}amide and a farnesyl transferase inhibitor | |
IL149496A (en) | Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract | |
HUP0101546A2 (hu) | Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére | |
WO2001001972A3 (en) | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | |
RU2000126790A (ru) | Композиция, предназначенная для лечения алкогольной и лекарственной зависимости, содержащая опиоидный антагонист и модулятор nmda рецепторного комплекса | |
HUP0003410A2 (hu) | Azapoliciklusos vegyületeket tartalmazó kombinációs gyógyszerkészítmények emlősök nikotinélvezetének megelőzésére és kezelésére | |
MY129668A (en) | Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes | |
JP2009500439A (ja) | 疼痛の治療のための相乗的組み合わせ(カンナビノイド受容体アゴニスト及びオピオイド受容体アゴニスト) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |